Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

The price of Teva Pharmaceutical stock has seen a rise of 14% in the last five trading days, while it is up 6% over the last month (twenty-one trading days). The recent rise came after the company announced a settlement with the state of Louisiana for opioid-related claims.

Is A Fall Imminent For Teva Stock After Its Recent Rally?

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 8 presentations examining Phase 2b/3 data, pooled analyses and open-label extension (OLE) study data for AJOVY (fremanezumab-vfrm) injection will be presented at the 25th World Congress of Neurology (WCN), taking place virtually on Oct. 3-7, 2021. “The data being presented at this year's WCN meeting aid in expanding our knowledge of migraine so we can continue to

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Inhaler Tales – a national campaign aimed at raising awareness about the role inhaler misuse may play in inadequate disease control.1 Central to the campaign is an animated inhaler voiced by actress, producer, and entrepreneur Sarah Michelle Gellar, who will share her own experience living with asthma and encourage others to take c

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD

The company reached a settlement in a legal dispute with the state of Louisiana.

Why Teva Pharmaceutical Industries Shot Higher Today

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Louisiana that settles the state's opioid-related claims. The agreement is contingent on confirmation from the state by November 2, 2021 that all political subdivisions will release Teva as part of the settlement. Under the terms of the settlement, Teva will pay Louisiana $15 million

Teva Reaches Agreement with Louisiana to Settle the State's Opioid-Related Claims

Bausch Health Companies Inc

Biogen

BioNTech SE

CRISPR Therapeutics

Moderna

Pfizer

Vertex Pharmaceuticals

Viatris

SPDR S&P Pharmaceuticals ETF

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

Genpact

General Motors

Kraft Heinz

Not everything goes up all the time on Wall Street, and no one expects that. Buyers of value stocks typically are prepared to wait for the longer term to play out.

5 Berkshire Hathaway Stocks in Downtrends

Teva has faced scandal after scandal which soured investors and the general public alike. Even though I think the $40.5 billion Actavis acquisition was a good move, it leveraged Teva to uncomfortable debt levels.

Teva: Cautiously Bullish On 5-Year Prospects

Merck

You can go big this month with these three pharmaceutical stocks.

3 Smartest Big Pharma Stocks to Buy in September

Mastercard

Riding the Oracle of Omaha's coattails has historically been a smart move for investors.

3 Discounted Buffett Stocks to Buy Hand Over Fist in September

The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance

The FDA has accepted Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.  TV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.

Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review

PARSIPPANY, N.J., TEL AVIV & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration (FDA). The acceptance is based on Phase 3 data from two pivotal studies:

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Showcasing Teva's Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache Federation Joint Congress 2021 Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 17 presentations, including one late-breake

Showcasing Teva's Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (deutetrabenazine) tablets in younger (

Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia

Teva stock bounced back to $10 after related opioid settlement news.

Why Teva Pharmaceuticals Has Two A-Products In The Bag

Teva is one of the largest pharmaceutical companies in the world and the second largest generic medicine company (after Viatris) in terms of revenue.

Teva: Maximum Optimism

DaVita

FedEx

Coca-Cola

Marsh & McLennan

SPDR S&P 500 ETF Trust

VeriSign

These Buffett stocks are suitable for a wide range of retail portfolios. Check out 7 of the Omaha Oracle's top stocks to buy for August.

The 7 Best Warren Buffett Stocks to Buy in August and Hold for Years

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call Transcript

Fate Therapeutics

GT Biopharma Inc

Hot biotech stocks to watch right now as cancer treatments make headlines in 2021. The post Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) Q2 sales reached $3.9 billion, increasing 1% Y/Y or decreasing 2% in local currency terms, missing the consensus of $4.04 billion. The decrease was mainly due to lower revenues in the North America segment, related primarily to Copaxone and Anda.

Teva Stock Falls After COVID-19 Impacts Q2 Top And Bottomline; Lowers FY21 Outlook

Teva Pharmaceutical Industries Ltd.'s shares slid 2.5% in premarket trade Wednesday, after the Israeli generics maker missed revenue estimates for the second quarter and lowered guidance, citing the continued impact of the pandemic.

Teva revenue falls short of estimates, lowers guidance as pandemic continue to weigh

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new report highlighting the billions of dollars saved by the healthcare system due to its generic medicines, and the Company's contribution to economies in 2020. Teva's Economic Impact Report, an independent study by Matrix Global Advisors (MGA), demonstrates how Teva, the leading provider of generic medicines, saved $43.1 billion across its major markets in 2020 alone. These major markets re

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis

Shares of Teva Pharmaceutical Indus (NYSE:TEVA) fell 2.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.27% year over year to $0.59, which were in line with the estimate of $0.59.

News for Teva Pharmaceutical Stock (TEVA)